Bagsværd, Denmark, 9 November 2012 Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) has completed its ...
Degludec vs glargine in type 2 diabetes Degludec is noninferior to glargine regarding the incidence of major cardiovascular events among patients with type 2 diabetes. Steven P. Marso, MD, from the ...
Combined insulin degludec/liraglutide lowers blood glucose and promotes weight loss without causing excess hypoglycemia among adults with type 2 diabetes who are not well-controlled using insulin ...
The authors say there has been a recent uptick in hosptial admissions from hypoglycemic events, and that a therapy to address this is needed. A review of 15 studies has found that insulin degludec, ...
Bagsværd, Denmark, 28 April 2022 – Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly ...
Please provide your email address to receive an email when new articles are posted on . A combination treatment containing ultra-long-acting insulin degludec and insulin aspart enhanced glucose ...
San Diego, CA - The new longer-acting diabetes drug insulin degludec (Novo Nordisk) improves long-term glycemic control with a lower rate of nocturnal hypoglycemia compared with insulin glargine ...
Please provide your email address to receive an email when new articles are posted on . The newer, long-acting basal insulin degludec was noninferior with respect to glycemic control compared with ...
Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial ‘Once-weekly insulin would be a remarkable step ...
Nov 8 (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday focused on heart safety and risk of hypoglycemia as it reviewed Danish drugmaker Novo Nordisk's new ...
(HealthDay News) — For patients with type 1 or type 2 diabetes, insulin degludec is associated with a reduced rate of hypoglycemic episodes compared with insulin glargine, according to 2 studies ...
The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results